PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026
Rhea-AI Summary
PROCEPT BioRobotics (Nasdaq: PRCT) will release its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time, accessible via webcast and archived for at least 90 days on the company’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – PRCT
In the Jul 15 session, PRCT declined 0.83%, reflecting a mild negative market reaction. Argus tracked a trough of -11.4% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Earnings date notice | Neutral | -0.3% | Scheduled Q1 2026 results release and post-close conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The prior earnings-date notice in April 2026 was followed by a small negative move of -0.3% on average.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by following one of the below links:
- Webcast link for interested listeners:
- Dial-in registration for sell-side research analysts:
Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com.
An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. In addition to its leadership in BPH treatment, the Company is pursuing clinical research initiatives in prostate cancer utilizing investigational applications of its robotic and AI-enabled technologies. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Investor Contact:
Marissa Bych
Managing Director
Gilmartin Group LLC
Marissa@gilmartinir.com
